Stock AnalizResmed Inc. RMD
Medical/Dental Instruments · data as of November 13, 2026
Resmed Inc. (RMD) is a healthcare company listed in the US with a market value of about $33.7B. In the twelve months to September 30, 2026 it had revenue of $5.7B and net income of $1.6B, a net margin of 27.8%.
Its overall Stock Analiz score is 4.2 out of 5 (excellent). The strongest part is track record (5/5); the weakest is value (3/5).
Key numbers: a P/E of 21.8, a price to free cash flow of 20.9, 5-year revenue growth of 12% a year, a 5-year average ROIC of 19%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 28% below the current price.
Score: 4.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7B | $5.7B | $5.1B | $4.7B | $4.2B | $3.6B | $3.2B | $3.0B | $2.6B | $2.3B | $2.1B |
| Net income | $1.6B | $1.5B | $1.4B | $1.0B | $898M | $779M | $475M | $622M | $405M | $316M | $342M |
| Free cash flow | $1.6B | $1.6B | $1.7B | $1.3B | $574M | $216M | $634M | $707M | $390M | $442M | $352M |
| EPS (diluted) | $10.98 | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 | $2.80 | $2.19 | $2.40 |
| Net margin | 27.8% | 26.9% | 27.2% | 21.8% | 21.2% | 21.8% | 14.8% | 21.0% | 15.5% | 13.5% | 16.6% |
| ROIC | — | 20.2% | 20.6% | 18.6% | 16.2% | 19.0% | 13.2% | 18.1% | 13.5% | 14.0% | 11.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 17 analysts is $264.33, 10% above the current price; targets range from $210.00 to $320.00; the consensus rating is “Buy”; expected EPS is $12.14 for the fiscal year ending June 30, 2027.
Frequently asked questions
What is Resmed’s P/E ratio?
About 21.8, based on the last twelve months of diluted earnings per share (forward P/E about 18.9).
Is Resmed stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 28% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Resmed pay a dividend?
Yes. The dividend yield is about 1.11%, and it has paid dividends for 10 years in our data.
Is Resmed a good stock to buy?
We do not give buy or sell advice. Resmed scores 4.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.